Best Stocks Under $20.00 for 2019

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $20.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $20.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $20.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Everi (NYSE:EVRI)

Stock Price: $7.67
Market Cap: $538.39 million
P/E Ratio: -24.7
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.1040 (31.7% Upside)

Everi Holdings Inc. provides technology solutions for the casino gaming industry in the United States, Europe, Canada, the Caribbean, Central America, and Asia. The company operates in two segments, Games and Payments. It offers gaming products, such as classic mechanical reel games, video reel games, core HDX, Empire MPX and the Texan HDX, wide area progressive games, and slot tournament systems; and sells player terminals, licenses, back office systems, and other related equipment. The company also provides Casino Cash Plus 3-in-1 ATM, a cash-dispensing machine that enables ATM cash withdrawals, POS debit card cash access transactions, and credit card cash access transactions; check verification and warranty services; CashClub that provides gaming establishments with a single dashboard interface to streamline credit and debit card cash access transaction processing and check warranty transactions; fully integrated kiosks that provide multiple functions to the casino floor; and other integrated kiosk solutions. In addition, it offers Central Credit, a gaming patron credit bureau service; Everi Compliance, a suite of compliance software to assist with anti-money laundering regulations, as well as assist casinos in filing required tax forms; non-ATM terminals that perform authorizations for credit card cash access and POS debit card transactions; database services; and an online payment processing solution for gaming operators in states that offer intra-state, and Internet-based gaming and lottery activities. The company was formerly known as Global Cash Access Holdings, Inc. and changed its name to Everi Holdings Inc. in August 2015. Everi Holdings Inc. was founded in 1998 and is headquartered in Las Vegas, Nevada.

#2 - Mesa Air Group (NASDAQ:MESA)

Stock Price: $9.39
Market Cap: $224.45 million
P/E Ratio: 7.6
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $16.60 (76.8% Upside)

Mesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc., which provides regional air carrier services under capacity purchase agreements with the American Airlines and the United Airlines. As of September 30, 2018, it operated a fleet of 145 aircraft with approximately 730 daily departures to 110 cities in the United States, Canada, Mexico, Cuba, and the Bahamas. The company was founded in 1982 and is headquartered in Phoenix, Arizona.

#3 - SUNDANCE ENERGY/S (NASDAQ:SNDE)

Stock Price: $2.86
Market Cap: $35.73 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $9.00 (214.7% Upside)

Sundance Energy Australia Limited engages in the exploration, development, and production of oil and natural gas in the United States. The company's exploration and development activities are focused on the Eagle Ford project in the South-Texas-Gulf Coast Basin. Sundance Energy Australia Limited was incorporated in 2004 and is based in Wayville, Australia.

#4 - Ocular Therapeutix (NASDAQ:OCUL)

Stock Price: $3.66
Market Cap: $151.09 million
P/E Ratio: -1.7
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $13.60 (271.6% Upside)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.

#5 - Viking Therapeutics (NASDAQ:VKTX)

Stock Price: $9.07
Market Cap: $648.14 million
P/E Ratio: -11.5
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $26.2857 (189.8% Upside)

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

#6 - Adaptimmune Therapeutics (NASDAQ:ADAP)

Stock Price: $4.94
Market Cap: $466.42 million
P/E Ratio: -6.2
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $16.00 (223.9% Upside)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

#7 - Evolent Health (NYSE:EVH)

Stock Price: $16.80
Market Cap: $1.38 billion
P/E Ratio: -24.0
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $32.4444 (93.1% Upside)

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management. Its services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

#8 - SeaSpine (NASDAQ:SPNE)

Stock Price: $16.42
Market Cap: $296.71 million
P/E Ratio: -6.4
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.50 (24.8% Upside)

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.

#9 - Energy Transfer LP Unit (NYSE:ET)

Stock Price: $15.05
Market Cap: $17.43 billion
P/E Ratio: 12.4
Dividend Yield: 8.13 %
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $19.6667 (30.7% Upside)

Energy Transfer LP provides diversified energy-related services in the United States. It owns and operates approximately 7,900 miles of natural gas transportation pipelines and three natural gas storage facilities in Texas; and approximately 11,800 miles of interstate natural gas pipelines. The company sells natural gas to electric utilities, independent power plants, local distribution companies, industrial end-users, and other marketing companies. It owns and operates natural gas and natural gas liquid (NGL) gathering pipelines, as well as natural gas processing plants, treating facilities, and conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, and Louisiana; natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas; a natural gas gathering system in Ohio; and transportation and supply of water to natural gas producers in Pennsylvania. The company also owns approximately 4,300 miles of NGL pipelines, 5 NGL and propane fractionation facilities, and NGL storage facilities with aggregate working storage capacity of approximately 53 million barrels. It also sells gasoline, middle distillates, and motor fuel at retail, as well as crude oil, NGLs, and refined products; operates convenience stores; and distributes motor fuels and other petroleum products. The company provides natural gas compression services; treating services, such as carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration, and British thermal unit management services; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalties, and generates a total of 75 megawatts electrical power. The company was formerly known as Energy Transfer Equity, L.P. and changed its name to Energy Transfer LP in October 2018. The company was founded in 2002 and is based in Dallas, Texas.

#10 - HTG Molecular Diagnostics (NASDAQ:HTGM)

Stock Price: $2.35
Market Cap: $66.98 million
P/E Ratio: -1.3
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.50 (219.1% Upside)

HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

#11 - Collegium Pharmaceutical (NASDAQ:COLL)

Stock Price: $14.79
Market Cap: $451.50 million
P/E Ratio: -6.0
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $32.40 (119.1% Upside)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

#12 - Intec Pharma (NASDAQ:NTEC)

Stock Price: $8.19
Market Cap: $261.95 million
P/E Ratio: -5.0
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.70 (55.1% Upside)

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

#13 - Nabriva Therapeutics (NASDAQ:NBRV)

Stock Price: $2.06
Market Cap: $1.38 billion
P/E Ratio: -0.8
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $11.1667 (442.1% Upside)

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

#14 - Synlogic (NASDAQ:SYBX)

Stock Price: $9.29
Market Cap: $236.41 million
P/E Ratio: -1.6
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.1667 (117.1% Upside)

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also involved in developing discovery-stage product candidates for inborn errors of metabolism, including maple syrup urine disease, isovaleric acidemia, and organic acidemias. It has a collaboration agreement with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; Ginkgo Bioworks to discover new living medicines to treat neurological and liver disorders. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

#15 - ConforMIS (NASDAQ:CFMS)

Stock Price: $1.26
Market Cap: $56.94 million
P/E Ratio: -1.7
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $2.8750 (128.2% Upside)

ConforMIS, Inc. is a holding company, which engages in the development, manufacture, and sale of joint replacement implants. Its products include iTotal, iUni and iDuo, and iJig Instrumentation. The company was founded Philipp Lang in 2004 and is headquartered in Bedford, MA.

#16 - Marinus Pharmaceuticals (NASDAQ:MRNS)

Stock Price: $3.82
Market Cap: $154.81 million
P/E Ratio: -4.8
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.50 (384.3% Upside)

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

#17 - ProQR Therapeutics (NASDAQ:PRQR)

Stock Price: $14.00
Market Cap: $542.02 million
P/E Ratio: -7.2
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $29.60 (111.4% Upside)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

#18 - Aptose Biosciences (NASDAQ:APTO)

Stock Price: $1.90
Market Cap: $71.77 million
P/E Ratio: -3.7
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.40 (236.8% Upside)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

#19 - Sientra (NASDAQ:SIEN)

Stock Price: $10.41
Market Cap: $297.72 million
P/E Ratio: -3.7
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.2857 (133.3% Upside)

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.

#20 - Evofem Biosciences (NASDAQ:EVFM)

Stock Price: $3.60
Market Cap: $93.12 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.70 (197.2% Upside)

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.